Biopharmaceutical company AbbVie has submitted a new drug application to the FDA for ABBV-951, a 24-hour subcutaneous treatment for motor fluctuations in patients with advanced Parkinson’s disease.
Per a company press release, the submission is based on positive results from a phase 3, head-to-head, randomized, controlled clinical trial in which approximately 130 adult participants with PD, whose motor symptoms were no longer adequately controlled by their current medications, were enrolled across 80 sites in the U.S. and Australia.
During the 12-week trial, participants received either